Browning is characterized by the formation of beige/brite fat depots in subcutaneous white adipose tissue (sWAT). This study aimed to examine whether the chronic activation of PPARalpha by fenofibrate could induce beige cell depots in the sWAT of diet-induced obese mice. High-fat fed animals presented overweight, insulin resistance and displayed adverse sWAT remodeling. Fenofibrate significantly attenuated these parameters. Treated groups demonstrated active UCP-1 beige cell clusters within sWAT, confirmed through higher gene expression of PPARalpha, PPARbeta, PGC1alpha, BMP8B, UCP-1, PRDM16 and irisin in treated groups. PPARalpha activation seems to be pivotal to trigger browning through irisin induction and UCP-1 transcription, indicating that fenofibrate increased the expression of genes typical of brown adipose tissue (BAT) in the sWAT, characterizing the formation of beige cells. These findings put forward a possible role of PPARalpha as a promising therapeutic for metabolic diseases via beige cell induction.
Introduction
The white adipose tissue (WAT), initially recognized as an energy storage organ, is currently conceived as a metabolically active endocrine and secretory tissue (Ahima, 2006) . The secretion of adipokines and its role in the regulation of energy and vascular homeostasis, the inflammatory response and glucose tolerance are altered in obese individuals (Tilg and Moschen, 2006; Wintour and Henry, 2006) .
Irisin, initially described as a myokine , was recently described as an adipokine that is secreted primarily by subcutaneous white adipose tissue (sWAT) (Roca-Rivada et al., 2013) . This protein could be a marker for white-brown fat plasticity, which is a phenomenon known as browning, characterized by the formation of beige adipocyte depots in the sWAT. Beige adipocytes are brown-like adipocytes with thermogenic capacity . Diet-induced obese animals express supra-physiological levels of irisin, indicating a possible resistance to irisin and the resulting impairment of its actions (Roca-Rivada et al., 2013) .
Recently, beige/brite cells have been identified in the sWAT of humans and rodents (Enerback, 2009; Ishibashi and Seale, 2010) . Chronic activation of peroxisome proliferator-activator receptor (PPAR)-gamma has been implicated in the conversion of white adipocytes into beige cells, a subset of adipocytes with particular molecular features and developmental origins (Petrovic et al., 2010) . This discovery shed light on the role that different PPAR isoforms exert upon browning and represents a promising therapeutic target to combat obesity provided that beige cells express thermogenic factors such as PR domain containing protein 16 (PRDM16) and bone morphogenetic protein 8B (BMP8B) (Spiegelman, 2013) .
The family of hypolipidemic drugs known as fibrates are important PPARalpha agonists (Vamecq and Latruffe, 1999) . In experimental studies, important pleiotropic effects have been observed with fenofibrate use such as body mass (BM) reduction, which reflects reduced body fat stores and increased insulin sensitivity (Fernandes-Santos et al., 2009; Harrington et al., 2007) . PPARalpha participates in lipid metabolism, and despite reducing adiposity in mice (Jeong and Yoon, 2009 ), the literature is scarce in associating fenofibrate administration with the metabolic profile and adipose tissue physiology. Obese animals treated with PPARalpha agonists could benefit from thermogenesis induction, as irisin seems to act through PPARalpha to activate uncoupling protein (UCP-1) .
These previous findings prompted us to examine whether chronic PPARalpha activation by fenofibrate could induce beige cell depots, which share metabolic features with brown adipose tissue (BAT), in the sWAT of diet-induced obese mice in vivo.
Material and methods

Animals and diet
Male C57BL/6 mice (3 months old) were maintained on a 12 h/ 12 h dark/light cycle with controlled humidity (60 ± 10%) and temperature (21 ± 2°C) in pathogen-free cages with free access to food and water. This study was in accordance with the conventional guidelines for experimentation with animals (National Institutes of Health Publication No. 85-23, revised in 1996) and was approved by the Animal Ethics Committee of the State University of Rio de Janeiro (Protocol Number CEUA/032/2013).
Mice were randomly assigned to receive a standard chow (SC: 14% protein, 10% fat, and 76% carbohydrates, total energy 15 kJ/g) or a high-fat diet (HF: 14% protein, 50% fat and 36% carbohydrates, total energy 21 kJ/g), n = 20 per group for 10 weeks. After that, treatment started and the SC and HF groups were subdivided into four groups (n = 10), as follows:
(a) SC group -untreated, fed SC diet; (b) SC-F group -SC diet treated with fenofibrate; (c) HF group -untreated, fed HF diet; (d) HF-F group -HF diet treated with fenofibrate.
Treatment lasted 5 weeks, and fenofibrate (Sigma-Aldrich, St. Louis, MO, USA) was mixed into the diet considering the mean BM and the mean food intake of each group in order to guarantee that the dose did not vary between the lean (SC-F) and obese (HF-F) treated groups. Then, the SC-F diet contained 0.09% (w/w) and the HF-F diet contained 0.117% (w/w) of fenofibrate, both of which corresponded to the dose of 100 mg/kg BM/day. The diets were manufactured by PragSolucoes (Jau, Sao Paulo, Brazil) and were in agreement with recommendations of the American Institute of Nutrition (AIN 93M) (Reeves et al., 1993) . Food intake was measured daily, and BM was measured weekly. Energy intake was obtained as the product of food consumption and the energy content of the diet.
Oral glucose tolerance test (OGTT)
The (OGTT) was performed after 6 h of food deprivation. Glucose (1.0 g/kg) was administered by orogastric gavage to induce glucose overload. Blood was collected by milking the tip of the tail at 0, 15, 30, 60 and 120 min following glucose administration, and blood glucose was measured using a glucometer (Accu-Chek, Roche, Germany). The area under the curve (AUC) was calculated for OGTT from 0 to 120 minutes using the trapezoid rule (GraphPad Prism version 6.05 for Windows, GraphPad Software, La Jolla, CA, USA) to assess glucose intolerance. The blood glucose level at time 0 was considered the fasting glucose level.
Sacrifice and tissue extraction
After 15 weeks on the diet (including 5 weeks of treatment), the animals were fasted overnight and then deeply anesthetized in a CO2 gas chamber. Blood samples were obtained by cardiac puncture, and centrifugation separated plasma (120 g for 20 min) at room temperature and stored individually at −20°C until assay.
The inguinal fat pad located at the lower part of the rib cage and the mid-thigh was considered sWAT, where browning was firstly described and where thermogenic capacity is more expressive (Wu et al., 2014; Young et al., 1984) . This tissue was carefully dissected, weighed and prepared for analysis. Portions of the sWAT were kept in a freshly prepared fixative solution (formaldehyde 4% w/v, 0.1 M phosphate buffer, pH 7.2) for 48 h and processed for light microscopy. Concomitantly, portions of the sWAT were rapidly frozen for molecular analysis by RT-qPCR. The adiposity index was calculated and determined as the ratio between the sum of the masses of all fat pads (epididymal, retroperitoneal and subcutaneous) divided by the total BM, represented as a percentage (Barbosa-da-Silva et al., 2012) .
Plasma analysis
Plasma concentrations of irisin, insulin and leptin were evaluated in duplicate with commercially available enzyme-linked immunosorbent assay kits (Mouse FNDC5/Irisin ELISA kit Cat. # SEN576Mu, Uscn Life Science Inc., Houston, Texas, USA; Rat/ Mouse Insulin ELISA kit Cat. #EZRMI-13K and Rat/Mouse Leptin ELISA kit Cat. #EZML-82K, Millipore, Missouri, USA) using Fluostar Omega equipment (BMG LABTECH GmbH, Germany).
Adipose tissue structure and morphometry
Formalin-fixed sWAT samples were embedded in Paraplast Plus (Sigma-Aldrich, St. Louis, MO, USA), sectioned at 5 μm and stained with hematoxylin and eosin. Ten non-consecutive random microscopic fields were analyzed per animal on a light DMRBE Leica microscope (Leica Microsystems GmbH, Wetzlar, Germany), using an Infinity 1-5c camera (Lumenera Co., Ottawa, ON, Canada). The mean diameter of at least 50 adipocytes per animal was measured using Image Pro Plus software v7.01 (Media Cybernetics, Silver Spring, MD, USA).
Immunofluorescence
After sWAT sample deparaffinization, antigen retrieval was performed with citrate buffer, pH 6.0, which was followed by blocking with ammonium chlorate and glycine 2%. Nonspecific binding was then blocked by incubating with 5% bovine serum albumin in phosphate-buffered saline. Afterward, sections were incubated with anti-UCP1 (anti-goat, SC-6529, Santa Cruz Biotechnology) antibodies. Secondary anti-goat Alexa fluor 488 conjugated antibodies were used. Slides were mounted with SlowFade (Invitrogen, Molecular Probes, Carlsbad, CA, USA) to maintain fluorescence. Control sections were obtained after the omission of the primary antibodies. A confocal laser-scanning microscope (Nikon C2, Nikon Instruments Inc., Tokyo, Japan) was used to assess the slices, and photomicrographs were obtained using ×40 planapochromatic objective (Nikon).
RT-qPCR
Total RNA was extracted from approximately 50 mg sWAT using Trizol reagent (Invitrogen, CA, USA). RNA quantity was determined using Nanovue (GE Life Sciences) spectroscopy, and 1 mg RNA was treated with DNAse I (Invitrogen). First-strand cDNA synthesis was performed using Oligo (dT) primers for mRNA and Superscript III reverse-transcriptase (both Invitrogen). Quantitative real-time PCR (RT-qPCR) was performed using a Biorad CFX96 cycler and the SYBR Green mix (Invitrogen). qPCR primers were designed using the Primer3 online software and are indicated in Table 1 . Beta-actin was used as an endogenous control to normalize selected gene expression. Efficiencies of RT-qPCR for the target gene and the endogenous control were approximately equal and were calculated from a cDNA dilution series. Real-time PCR reactions were conducted as follows: after a pre-denaturation and polymerase-activation program (4 min at 95°C), forty-four cycles each consisting of 95°C for 10 s and 60°C for 15 s were followed by a melting curve program (60-95°C with heating rate of 0.1°C/s). Negative controls consisted of wells in which cDNA was substituted for deionized water. The relative mRNA expression ratio (RQ) was calculated using the 2 −ΔΔct equation in which 2ΔCT expresses the difference between the number of cycles (CT) of the target genes and the endogenous control.
Data analysis
Values are expressed as the means and the standard error of mean (SEM). In the cases where we could confirm homoscedasticity of variances, comparisons among groups were made by a t-test or ANOVA followed by Holm-Sidak post-hoc test. Comparisons within the same group at different times during the experiment were tested with repeated measures one-way ANOVA and post hoc Sidak test. Interactions between diet and treatment were tested with twoway ANOVA. A P-value ≤0.05 was considered to be statistically significant (GraphPad Prism version 6.05 for Windows).
Results
Body mass and food behavior
The SC and HF groups demonstrated no significant difference in their initial BM at the beginning of the experiment. After 1 week of diet administration, the HF group had higher BM than the SC group (+12%, P < 0.05), which continued to increase until 10 weeks of diet intake (+26%; P < 0.0001). Repeated measures one-way ANOVA revealed differences between baseline and pre-treatment (10 weeks of diet intake) BM in SC (P = 0.0021) and HF groups (P = 0.0017). After 1 week of treatment, both treated groups demonstrated a significant decrease in BM compared with their counterparts. The SC-F group weighed 9% less than the SC group (P < 0.05), and the HF-F group weighed 11% less than the HF group (P < 0.05). At the end of the experiment, after 5 weeks of treatment, the SC-F and HF-F groups were 14% and 16% lighter, respectively, than their counterparts (P = 0.0004 and P < 0.0001). Interestingly, in the last week of the experiment, the HF-F group demonstrated no significant difference in BM compared with the SC group (Fig. 1) . Repeated measures oneway ANOVA showed differences between pre-treatment and posttreatment (after 5 weeks of drug treatment) BM only in SC-F (P = 0.0058) and HF-F groups (P = 0.0002). No interaction between diet and treatment was observed regarding final BM, but diet and treatment influenced BM independently (two-way ANOVA, P < 0.0001).
The average weekly food intake in grams was not significantly different between the four groups over the 15-week experimental period ( Table 2) . As for treated groups, SC-F animals ingested 2.93 g of SC-F diet/day on average, which corresponded to 2.64 mg of fenofibrate per day. Since SC-F mice weighed 26.38 g on average during the treatment, this dose of fenofibrate corresponded to 100.25 mg/Kg BM. HF-F group had an average ingestion of 2.76 g of HF-F diet/day, corresponding to 3.22 mg of fenofibrate per day. Considering the average BM of 31.66 g, the dose of fenofibrate was 101.98 mg/kg BM in the HF-F group. Both doses were not statistically different. Energy intake was greater in the HF and HF-F groups than in their counterparts (+17% and +21%; P < 0.05), as indicated by calculating the energy provided by the diets based on their energy density (Table 2 ). Of note, there was no difference in energy intake between the SC and SC-F groups or between the HF and HF-F groups. This fact was confirmed by no interactions between diet and treatment regarding energy intake as only diet influenced this parameter (two-way ANOVA, P = 0.0004). These observations exclude the need for pair-feeding groups to isolate the effects of reduced energy intake upon the analyzed outcomes.
Carbohydrate metabolism
The HF group presented higher fasting glucose values than the SC and SC-F groups (+25% and +41%; P < 0.05), while the treated groups demonstrated decreased fasting glucose levels than their counterparts (−11% for SC-F and −13% for HF-F; P < 0.05) ( Table 2) . Diet and treatment independently influenced fasting glucose levels, without exhibiting significant interaction between these two variables (two-way ANOVA, P < 0.001).
The OGTT results were in accordance with the fasting glucose result as the HF group had a greater AUC, indicating glucose intolerance, compared with the SC and SC-F groups (+33% and +86%; P < 0.001). Fenofibrate treatment in SC-F and HF-F groups minimized glucose intolerance compared with the untreated groups (−29% and −19%; P < 0.05). Once again, diet and treatment influenced AUC values separately, but with no interaction (two-way ANOVA, P < 0.0001). It is significant that SC, HF, and HF-F groups presented differences between time 0 and time 15 of OGTT (repeated measures one-way ANOVA, P < 0.002). HF group showed a long lasting glucose peak, with no differences between time 15 and time 30, configuring intolerance to glucose. Conversely, HF-F group showed significant difference between times 15 and 30 (repeated measures one-way ANOVA, P < 0.0001), implying a faster and more gradual reestablishment of fasting glucose values and indicating a standard tolerance to glucose upload. OGTT results are found in Fig. 2 .
Hormones (plasma analyses)
The HF group presented with hyperinsulinemia compared with the SC group (+97%; P < 0.0001), and the treatment normalized this parameter in the HF-F group compared with the HF group (−67%; P < 0.05). Diet and treatment influenced in an independent way the insulin levels, without interaction (two-way ANOVA, P < 0.0001).
Likewise, leptin levels in the HF group were increased compared with the SC and SC-F groups, featuring hyperleptinemia (+250%; P < 0.0001 and +833%; P < 0.0001, respectively), and treatment normalized this parameter in the HF-F group compared with the HF group (−272%; P < 0.0001). Both the diet and treatment interacted to determine leptin levels, besides influencing independently this parameter (two-way ANOVA, P < 0.0001). These results are demonstrated in Table 2 .
Irisin levels were elevated in treated groups when compared to their counterparts (+48% and +65%; P < 0.005) as showed in Table 2 . It is important to highlight that only treatment exerted influence upon the plasma irisin levels.
Adiposity index
The adiposity index was elevated in the HF group compared with the SC and SC-F groups (+224% and +333%; P < 0.0001). However, the SC-F and HF-F groups had a smaller adiposity index (−67%; P < 0.05 and −309%, P < 0.0001) than their counterparts (Table 2) . There was a significant interaction between diet and treatment as well as an independent influence of both variables upon adiposity index (two-way ANOVA, P < 0.0001).
sWAT adipocyte diameter and histology
Adipocytes from the HF group were considerably enlarged compared with the SC and SC-F groups (+91% and +136%; P < 0.0001) as diet exerted influence on the parameter (two-way ANOVA, 
Fig. 2. Oral glucose tolerance test (OGTT) curve (A) and area under the curve of OGTT (B).
Values are the means ± SEM, n = 5. Significant differences among the different groups at the same time of evaluation are indicated by symbols (P < 0.05) and were determined by a one-way ANOVA and post-hoc Holm-Sidak test: a ≠ SC; b ≠ SC-T and c ≠ HF. In OGTT curve, differences between two successive times of glucose evaluation from each group were tested by repeated measures one-way ANOVA and post-hoc Sidak test (P < 0.05): § different from time 0, * different from time 15, # different from time 30 and ¥ different from time 60.
P < 0.0001). The SC-F and HF-F groups presented adipocytes of decreased size (−23%, P < 0.05 and −104%, P < 0.0001) compared with their counterparts. This observation ensures the independent influence of treatment on the adipocyte size (two-way ANOVA, P < 0.0001). Both factors (diet and treatment) interacted to normalize adipocyte diameter in HF-F group, reaching values comparable to SC group (Table 2) . The photomicrographs in Fig. 3A -D demonstrate sWAT histology in a unilocular cellular conformation in the non-treated groups. The presence of beige cell clusters in the treated groups is noteworthy and suggests the occurrence of a phenomenon known as "browning". Both SC-F and HF-F have areas of multilocular adipose tissue within the characteristic unilocular white adipose tissue cells, which have been called beige adipose tissue.
Immunofluorescence
Beige cell presence was confirmed in the SC-F and HF-F groups by active immunofluorescent UCP1 staining in the sWAT of these groups. Conversely, subcutaneous white adipocytes from untreated SC and HF groups did not demonstrate this pattern of immunoreactivity as UCP1 is closely related to thermogenesis and is markedly expressed in brown adipocytes. These data are depicted in Fig. 3E-H. 
RT-PCR
Fenofibrate treatment promoted enhanced PPARalpha and PPARbeta gene expression in the SC-F and HF-F groups compared with the SC and HF groups (PPARalpha: +452% and +234%; P < 0.05; PPARbeta: +450% and +313%; P < 0.05). This fact was confirmed by the independent influence that treatment exerted upon both transcription factors gene expression (two-way ANOVA, P < 0.01), without influence from diet or interaction between both factors. The increased gene expression of both PPAR isoforms was directly related to the increase in PGC1alpha gene expression, which was also risen in the SC-F and HF-F groups compared with their counterparts (+340%; P < 0.0001 and +177%; P < 0.05, Fig. 4) . Along with PPARalpha and PPARbeta, PGC1alpha gene expression was also influenced only by the treatment (two-way ANOVA, P < 0.01). PRDM16, a marker for beige cells and brown adipose tissue, was potentially increased in both treated groups compared with the SC and HF groups (+285% for SC-F and +365% for HF-F, P < 0.05), suggesting the presence of beige cells in the sWAT after fenofibrate treatment. In fact, treatment was the only factor that exerted influence on PRDM16 gene expression (two-way ANOVA, P < 0.007). Similarly, BMP8B, which is associated with a thermogenic signaling pathway and is typically expressed in BAT, was increased in the HF-F group compared with the HF group (+534%; P < 0.0001) and to the other groups, indicating the presence of brown-like adipocytes after fenofibrate treatment in the HF diet group (Fig. 5) . BMP8B gene expression was influenced by diet and treatment independently and also both factors interacted to determined its levels (two-way ANOVA, P < 0.001).
Our results demonstrate in an unprecedented way an increase in irisin gene expression, which acts through PPARalpha to activate UCP-1 transcription after fenofibrate treatment in the SC-F and HF-F groups compared with their counterparts (+375% and +366%; P < 0.05). This result agrees with the increase in UCP-1 gene expression in the SC-F and HF-F groups compared with their counterparts (+365% and +220% P < 0.05, Fig. 5 ). Both irisin and UCP-1 gene expression were influenced independently by diet and Fig. 3 . Subcutaneous white adipose tissue immunofluorescence and hematoxylin and eosin staining, same magnification (bar = 50 μm). Upper panels show the histology of the untreated SC group (A) with typical unilocular adipocytes with regular size; followed by the untreated HF group (B) with hypertrophied unilocular adipocytes; the SC-F group (C), depicting areas of browning characterized by multilocular adipocytes (beige cells) and normal sized unilocular adipocytes; and the HF-F group (D) in the upper-right panel, presenting areas of multilocular adipocytes (beige cells) and normal sized unilocular adipocytes. Lower panels depict the untreated SC group (E) without significant positive UCP1 immunoreactivity; followed by the untreated HF group (F), which did not express UCP1 and had considerable distances between nuclei (blue), confirming adipocyte hypertrophy; the SC-F group (G), depicting areas of browning, characterized by marked UCP1 expression by beige cells (green); and the HF-F group (H), presenting areas of beige cells that markedly expressed UCP1 and close nuclei, implying regular sized adipocytes. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.) treatment, without interaction between these two variables (twoway ANOVA, P < 0.05).
Discussion
In the present study, we identified fenofibrate as a likely inducer of beige cell formation in the sWAT. The current findings indicate that obese animals treated with fenofibrate benefit from weight loss, enhanced insulin sensitivity, and marked expression of brown fat specific genes in the sWAT (UCP1, BMP8B and PRDM16) coupled with UCP-1-positive beige adipocytes in the sWAT. These data give rise to the idea that PPARalpha might orchestrate the formation of beige cells in the sWAT along with irisin and PGC1alpha in this model as depicted in Fig. 6 . Considering BM, fenofibrate yielded a pronounced weight loss, as has been previously reported in the literature (Fernandes-Santos et al., 2009; Srivastava et al., 2006) ; however, the pathway by which this occurred remained to be unraveled. The treated animals had similar energy intake as the untreated animals, thus reinforcing that the reduced BM is a direct result of drug action and discards the need for a pair-fed group.
BM reduction in fenofibrate-treated animals is associated with reduced fat pad mass, which is implicated in tackling insulin resistance Souza-Mello et al., 2010) . Moreover, reduced adipocyte size after fenofibrate treatment correlated inversely with insulin sensitivity and can be accounted for by higher β-oxidation through PPARalpha activation, which triggers enhanced mitochondrial input of fatty acids for metabolization (Jeong and Yoon, 2009; Tenenbaum et al., 2005) .
Hyperleptinemia, found in untreated obese animals, was countered by fenofibrate administration. Normalization of leptin levels restored its capacity to suppress insulin release at the postprandial stage, thus normalizing insulin levels and restoring insulin sensitivity in addition to eliciting appetite and energy expenditure regulation (Vickers et al., 2001; Yadav et al., 2013) . In compliance with the restoration of leptin and insulin levels in treated groups, irisin levels were increased by the treatment with fenofibrate in lean and obese treated animals, eliciting improvement of obesity and glucose homeostasis . Moreover, increased numbers of small adipocytes in parallel to reduced numbers of hypertrophied adipocytes were found after fenofibrate treatment, as has been previously reported (Jeong and Yoon, 2009) , and suggest a role for fenofibrate in adipose tissue remodeling.
In this context, the presence of multilocular beige adipocyte clusters in the sWAT of fenofibrate-treated obese animals was confirmed by enhanced thermogenic BAT-related markers gene expression in the sWAT. These data suggest an important role for PPARalpha in sWAT browning.
In addition to enhancing PPARalpha gene expression in sWAT, fenofibrate also induced higher PGC1alpha gene expression, which is a co-activator of all PPAR isoforms (Russell, 2005; Vega et al., 2000) . Thus, fenofibrate-treated animals also benefited from higher PPARbeta gene expression. PPARbeta induction by fenofibrate seemed to occur indirectly through enhanced PGC1alpha expression and deserves to be better addressed. PGC1alpha mediates mitochondrial biogenesis, thermogenesis and fatty-acid oxidation in BAT, where it is typically expressed (Handschin and Spiegelman, 2006) . Hence, increased PGC1alpha expression in the sWAT of fenofibratetreated animals denotes the presence of beige cells, confirming the central role that this transcriptional regulator of mitochondrial biogenesis plays in the browning phenomenon (Kleiner et al., 2012) . It is noteworthy that PPARbeta also exerts beneficial effects such as eliciting the preference for lipids as a cellular fuel instead of carbohydrates coupled with sustained adrenergic stimulation and the resulting higher thermogenesis (He et al., 2010; Ngala et al., 2011) .
Beige cells express a gene profile resembling that of brown adipose tissue, which enables these cells to dissipate energy as heat (Spiegelman, 2013) . The gene expression of PRDM16, a transcriptional co-activator that characterizes the brown lineage of adipose tissue, is coordinated by PPARalpha (Hondares et al., 2011) and can induce browning of sWAT (Seale et al., 2007 . PRDM16 can enhance the expression of representative BAT genes in the sWAT and suppress genes related to the WAT phenotype . Recently, PRDM16 was described as a pivotal factor for maintenance of the beige phenotype and thermogenic activity in sWAT as PRDM16 knockout animals kept their thermogenic activity in BAT. However, beige cells from these animals returned to the typical unilocular white adipocyte form in the absence of PRDM16 (Cohen et al., 2014) . In the present study, PPARalpha activation by fenofibrate induced PGC1alpha, and both of these seem to be involved in augmented PRDM16 expression in the sWAT of the treated groups, which characterizes beige cells.
Along with PRDM16, BMP8B, whose expression is also mediated by PPARalpha in BAT, was augmented in the sWAT of fenofibratetreated obese animals (Whittle et al., 2012) . In the present study, Fig. 4 . Gene expression, in subcutaneous white adipose tissue, of PPARalpha (A), PPARbeta (B), and PGC1alpha (C). Beta-actin was used as an internal control to normalize selected gene expression. The data are represented as the means ± SEM, n = 5 per group. Significant differences among the groups are indicated by symbols (P < 0.05) and were determined by a one-way ANOVA and post-hoc Holm-Sidak test: a ≠ SC; b ≠ SC-T and c ≠ HF.
the PPARalpha agonist stimulated BMP8B gene expression especially in the HF-treated group, as diet and treatment interacted significantly in this parameter. BMP8B induction is an important triggering stimulus for the adrenergic response, which increases the thermogenic capacity of the sWAT (Whittle et al., 2012) . Our results point to the potential role of BMP8B as a regulator of adipogenesis, favoring the increased expression of thermogenic markers such as UCP-1, which were clearly localized in the sWAT of SC-F and HF-F groups after treatment via immunofluorescence. These observations confirm the presence of beige cells in the sWAT.
Beige cells exhibit a particular gene expression profile as they demonstrate higher UCP-1 induction after cAMP stimulation than brown adipose cells, characterizing higher thermogenic activity . A recent study correlated PGC1alpha overexpression with enhanced browning-related gene expression in the sWAT, including UCP-1 . In the present study, fenofibrate treatment induced higher PGC1alpha gene expression, which is a potent inducer of irisin (Spiegelman, 2013) , leading to UCP-1 induction . The enhanced UCP-1 gene expression is positively correlated with irisin gene expression in our treated groups, given that this adipokine seems to induce thermogenesis via PPARalpha (Komatsu et al., 2010; Roca-Rivada et al., 2013) . In vitro studies demonstrate that white adipocytes differentiate UCP-1-positive adipocytes after irisin stimulation Spiegelman, 2013) . A proposed mechanism involves irisin and UCP-1 and relies on PPARalpha, considering that the inhibition of this transcription factor using a selective antagonist is capable of limiting browning even after irisin treatment. Hence, it can be argued that UCP-1 and browning are mediated, at least in part, by PPARalpha .
Our results revealed enhanced PGC1alpha expression after PPARalpha activation by fenofibrate. PPARalpha induces irisin and triggers UCP-1. This gene expression profile was exhibited by both treated groups, suggesting an effect of fenofibrate on these variables. Considering that adaptive thermogenesis relies on uncoupling proteins from the inner mitochondrial membrane (Crowley and Vidal-Puig, 2001 ), UCP-1 induction after fenofibrate treatment enabled sWAT to acquire characteristics of a metabolically active tissue, the beige adipose tissue. Of note, BAT in adult humans resembles beige adipose tissue, and therefore, rodent models with beige adipocyte induction are useful for translational research aiming to identify new strategies to increase energy expenditure and promote weight loss (Ishibashi and Seale, 2010; Spiegelman, 2013) .
The present findings suggest new pleiotropic effects of fenofibrate, which was initially described as a hypolipidemic drug. In addition to enhancing PPARalpha expression, fenofibrate also increased PPARbeta and irisin gene expression. The latter seems to be crucial for the induction of browning, resulting in brown-like cells, which have been associated with protection against obesity and related disease.
Conclusion
Taken together, our results indicate that fenofibrate minimized diverse deleterious metabolic parameters such as glucose intolerance, hyperleptinemia and adipocyte hypertrophy and is suitable . Beta-actin was used as an internal control to normalize selected gene expression. The data are represented as the means ± SEM, n = 5 per group. Significant differences among the groups are indicated by symbols (P < 0.05) and were determined by a one-way ANOVA and post-hoc Holm-Sidak test: a ≠ SC; b ≠ SC-T and c ≠ HF.
as a coadjutant for obesity management. Our main finding was that the fenofibrate enhanced the expression of genes typically found in brown adipose tissue in subcutaneous white adipose tissue, resulting in beige cell formation. Additionally, these cells exhibited marked expression of UCP1, confirming their phenotypic resemblance to brown adipocytes. This event seems to be mediated by irisin induction after PPARalpha activation. New studies will be necessary to produce translational approaches to elucidate the possible role of PPARalpha as a promising therapeutic target for metabolic diseases by beige cell induction.
